Veradigm announces new share repurchase program and initial financial guidance for fiscal 2023

Chicago--( business wire )--veradigm inc. (nasdaq: mdrx), formerly allscripts healthcare solutions, inc., announced today that its board of directors has approved a new share repurchase program under which veradigm may purchase up to $250 million of its common stock. the new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. in the fourth quarter of 2022 veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million.
MDRX Ratings Summary
MDRX Quant Ranking